The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
暂无分享,去创建一个
Bandana Sharma | Wenchao Wang | Nathanael S Gray | Hannah Webber | Albert Hallsworth | Yann Jamin | Louis Chesler | Simon P Robinson | Qingsong Liu | Rani E George | N. Gray | Qingsong Liu | S. Robinson | S. Rodig | N. Cheung | A. Perez-Atayde | B. Hallberg | S. Eccles | Y. Jamin | L. Moreau | K. Barker | A. Hallsworth | L. Chesler | R. George | B. Sharma | T. Sanda | Andrew D J Pearson | Takaomi Sanda | Antonio Perez-Atayde | Suzanne A Eccles | Nai-Kong Cheung | Bengt Hallberg | Scott Rodig | A. Pearson | Wen-chao Wang | Karen Barker | Zai Ahmad | Evon Poon | H. Webber | E. Poon | Teeara Berry | William Luther | Namrata Bhatnagar | Desheng Pei | Winston R Vetharoy | Lisa Moreau | Florence Raynaud | Desheng Pei | Zai Ahmad | W. Luther | Teeara Berry | N. Bhatnagar | Winston Vetharoy | F. Raynaud | Bandana Sharma | Namrata Bhatnagar
[1] M. Brilliant,et al. 5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[2] R. Palmer,et al. Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.
[3] L. Penn,et al. Negative autoregulation of c‐myc transcription. , 1990, The EMBO journal.
[4] R. Beijersbergen,et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.
[5] Frank Speleman,et al. Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.
[6] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[7] S. Evans,et al. Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Verrucous Carcinoma of the Vulva , 2012 .
[8] A. Biankin,et al. SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability , 2011, PLoS genetics.
[9] D. Rowitch,et al. Neuroblastoma Mycn Protein and Blocks Malignant Progression in Inhibition of Phosphatidylinositol 3-Kinase Destabilizes , 2006 .
[10] I. Wierstra,et al. The c-myc promoter: still MysterY and challenge. , 2008, Advances in cancer research.
[11] Roberto Piva,et al. The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.
[12] S. Ogawa,et al. Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.
[13] C. Arvanitis,et al. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. , 2006, Seminars in cancer biology.
[14] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[15] Huaqing Zhao,et al. Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma , 2011, Science Translational Medicine.
[16] D. Neuberg,et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.
[17] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[18] Y Taya,et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.
[19] D. Sabatini,et al. Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer , 2011 .
[20] G. Mohapatra,et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.
[21] R. Palmer,et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. , 2006, Gene expression patterns : GEP.
[22] K. Matthay,et al. Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma , 2012, Science Translational Medicine.
[23] O. Perez,et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. , 2008, Cancer research.
[24] Stella Pelengaris,et al. c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.
[25] K. Pulford,et al. Anaplastic lymphoma kinase proteins in growth control and cancer , 2004, Journal of cellular physiology.
[26] A. Peaston,et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Lowe,et al. The p53–Bcl-2 connection , 2006, Cell Death and Differentiation.
[28] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[29] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[30] G. Evan,et al. Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.
[31] J. Christensen,et al. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells , 2012, Oncogene.
[32] William Pao,et al. ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.
[33] M. Saarma,et al. Functional Characterization of Two Splice Variants of Rat Bad and Their Interaction with Bcl-w in Sympathetic Neurons , 2001, Molecular and Cellular Neuroscience.
[34] G. Evan,et al. The ups and downs of Myc biology. , 2010, Current opinion in genetics & development.
[35] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[36] W. London,et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[38] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[39] M. Hogarty,et al. BH3 Response Profiles From Neuroblastoma Mitochondria Predict Activity of Small Molecule Bcl-2 Family Antagonists , 2009, Cell Death and Differentiation.
[40] D. Gary Gilliland,et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.
[41] William C Hahn,et al. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. , 2005, Developmental cell.
[42] Wei Zheng,et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.
[43] W. Weiss,et al. Myc proteins as therapeutic targets , 2010, Oncogene.
[44] J. Trent,et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.